Key facts
- InflammX’s last known valuation is $39.1M (Jan 2021).
- It has raised $97.7M; the latest was Later Stage VC ($5.8M) in Feb 2025.
- Notable investors include Aspire NZ Seed Fund, Auckland UniServices, ExSight Ventures, University of London.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for InflammX
- ·The full record, as it builds
Funding rounds
No funding rounds for InflammX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About InflammX
Developer of an orally administered compound designed to inhibit the dysregulated inflammasome pathway of autoinflammation. The company's product offers disease modification by inhibiting the pathway by normalizing prematurely open pathological hemichannels in the cell membrane that release into the extracellular space, which is a signal for activation and release of multiple proinflammatory cytokines, helping healthcare providers to treat diabetic macular edema, macular degeneration, and chronic kidney diseases.
- Sector
- Healthcare
- HQ
- Tampa, FL, United States
- Founded
- 2005
- Employees
- 4
- Website
- inflammx.com/
- Ownership
- Privately Held (backing)
InflammX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InflammX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InflammX in its N-PORT filings yet. We sweep new filings monthly.